# US 2025/0145973 A1 · Conditioned dna modifying enzyme comprising heterologous dna binding domain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0145973 A1
- Document ID: US20250145973A1
- Status: Published application
- Kind: A1
- Application number: 18/916,979
- Filed: 2024-10-16
- Published: 2025-05-08
- Earliest claimed: 2023-10-16
- Assignees: Technische Universität Dresden, Korperschaft des offentlichen Rechts
- Applicants: Technische Universität Dresden Körperschaft des öffentlichen Rechts
- Inventors: Liliya MUKHAMETZYANOVA; Frank BUCHHOLZ; Julia TORRES RIVERA
- Web page: https://patentgrep.com/patent/US20250145973A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- C12N 15/1058: {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/85: for animal cells
- C12N 15/907: {in mammalian cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a method of identifying an amino acid position of a DNA modifying enzyme for insertion of a heterologous DNA binding domain (DBD), the method comprising the steps of providing a library of DNA modifying enzymes, wherein the members of the library comprise heterologous amino acid sequence insertions throughout the DNA modifying enzyme; identifying those DNA modifying enzymes of the library that have DNA modifying activity; and identifying the position of the insertion in those DNA modifying enzymes identified in the previous step. The present invention further pertains to methods of producing DNA modifying enzymes comprising an inserted heterologous DBD, to methods for modifying a nucleic acid sequence in a cell, and to methods for evolving a DNA binding domain on desired target sequences. Further provided are nucleic acid sequences encoding such DNA modifying enzymes and DNA binding domains, respective vectors and host cells.

## Claims

### Claim 1

A method of identifying an amino acid position of a DNA modifying enzyme for insertion of a heterologous DNA binding domain (DBD), the method comprising the steps of:
(i) providing a library of DNA modifying enzymes, wherein the members of the library comprise heterologous amino acid sequence insertions throughout the DNA modifying enzyme;
(ii) identifying those DNA modifying enzymes of the library that have DNA modifying activity; and
(iii) identifying the position of the insertion in those DNA modifying enzymes identified in step (ii).

### Claim 2 (depends on 1)

The method according to claim 1, wherein the one or more positions of the insertions identified in step (iii) are mapped to structural data of the DNA modifying enzyme and/or wherein the library of DNA modifying enzymes provided in (i) is encoded by a nucleic acid library, optionally wherein step (iii) comprises determining at least part of the nucleic acid sequence encoding those DNA modifying enzymes identified in step (ii), and/or
the method further comprising the step of selecting one or more amino acid positions for insertion of the heterologous DBD that are surface exposed in the DNA modifying enzyme and in proximity to the DNA binding site of the DNA modifying enzyme, and/or
wherein the heterologous amino acid sequence comprised in each of the members of the library of DNA modifying enzymes independent of each other have a length of between three and ten amino acids, optionally a length of five amino acids.

### Claim 3 (depends on 1, 2)

A method of producing a DNA modifying enzyme comprising an insertion of a heterologous DBD, the method comprising the steps of:
(i) inserting a nucleic acid sequence encoding the heterologous DBD into a nucleic acid sequence encoding the DNA modifying enzyme at the nucleotide triplet(s) encoding the one or more positions identified in the method of claims 1 or 2; and
(ii) expressing the nucleic acid sequence produced in step (i).

### Claim 4 (depends on 3)

The method according to claim 3, wherein the nucleic acid sequence encoding the heterologous DBD further comprises a nucleic acid sequence encoding a peptide linker upstream and a peptide linker downstream of the nucleic acid sequence encoding the heterologous DBD; optionally wherein the linker is a glycine-serine linker, optionally a glycine-serine linker with at least one G to R substitution.

### Claim 5 (depends on 1, 2, 3, 4)

The method according to any one of claims 1 to 4, wherein the DBD is a zinc-finger (ZF) DBD or a transcription activator-like effector (TALE) DBD, and/or wherein the DNA modifying enzyme is a transposase or a recombinase, optionally a serine recombinase or a tyrosine recombinase, optionally a tyrosine recombinase.

### Claim 6 (depends on 3, 4, 5)

A DNA modifying enzyme comprising an insertion of a heterologous DBD,
obtained by a method according to any one of claims 3 to 5, and/or
wherein
(i) the DNA modifying enzyme is Cre or a Cre-derived recombinase and the DBD is inserted between amino acid positions 278 and 279; or
(ii) the DNA modifying enzyme is Vika or a Vika-derived recombinase and the DBD is inserted between amino acid positions 172 and 173; or
(iii) the DNA modifying enzyme comprises an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 5, 9 to 13, 19, 20, 22, 30, 41, 42, 51, 64 and 91 to 200.

### Claim 7

A DNA modifying enzyme comprising an insertion of a heterologous DBD, wherein the DBD optionally comprises at its N- and/or C-terminus a peptide linker, wherein the DNA modifying enzyme is inactive on its target site when the heterologous DBD does not bind to its target DNA, and wherein the DNA modifying enzyme is active on its target site when the heterologous DBD binds to its target DNA.

### Claim 8 (depends on 6, 7)

A nucleic acid or a plurality of nucleic acids encoding the DNA modifying enzyme according to claim 6 or 7.

### Claim 9 (depends on 8)

An expression vector comprising the nucleic acid or plurality of nucleic acids according to claim 8.

### Claim 10 (depends on 8, 9)

A host cell or culture of host cells comprising the nucleic acid or plurality of nucleic acids according to claim 8, or the expression vector according to claim 9, optionally wherein the host cell expresses the DNA modifying enzyme encoded by the nucleic acid or plurality of nucleic acids.

### Claim 11 (depends on 6, 7, 8, 9, 10)

A pharmaceutical composition comprising the DNA modifying enzyme according to any one of claims 6 or 7, the nucleic acid or plurality of nucleic acids according to claim 8, the expression vector according to claim 9, or the host cell or culture of host cells according to claim 10, and a pharmaceutically acceptable excipient or carrier.

### Claim 12

(canceled)

### Claim 13 (depends on 6, 7, 8, 9, 10, 11)

A method for modifying a nucleic acid sequence of interest, comprising contacting a cell or tissue comprising the nucleic acid sequence of interest with the DNA modifying enzyme according to any one of claims 6 or 7, the nucleic acid or plurality of nucleic acids according to claim 8, the expression vector according to claim 9, the host cell or culture of host cells according to claim 10, or the pharmaceutical composition according to claim 11 under conditions allowing the DNA modifying enzyme to modify the nucleic acid sequence of interest.

### Claim 14 (depends on 1, 2)

Method of changing the specificity and/or activity of a DNA modifying enzyme comprising the steps of:
(i) identifying an amino acid position of a DNA modifying enzyme for insertion of a heterologous DBD according to the method of claim 1 or 2; and
(ii) inserting a heterologous DBD at the position identified in step (i).

### Claim 15

Method of evolving a DBD on a target sequence of interest, comprising the steps of:
(i) creating a library of variants of the DBD;
(ii) cloning the library of step (i) into expression vectors comprising a first region encoding a DNA recombining enzyme, a second region comprising a first target site of said DNA recombining enzyme and regions flanking said first target site, and a third region comprising a second target site of said DNA recombining enzyme and regions flanking said second target site, such that a DBD is inserted directly or via peptide linkers into the DNA recombining enzyme, wherein the first, second and third regions are separated from another;
(iii) introducing the expression vectors into host cells and culturing the host cells, thereby expressing the encoded DNA recombining enzyme comprising the DBD;
(iv) isolating plasmids from the cell culture of step (iii) and determining whether the DNA recombining enzyme catalyzed a recombination reaction at both target sites on the vector;
(v) amplifying the DBD of those plasmids that were found to encode a DNA recombining enzyme comprising the DBD showing recombination activity using error-prone PCR to generate a new library of variants of the DBD;
(vi) repeating steps (ii) to (iv) with the library of step (v).

### Claim 16

A DNA modifying enzyme comprising an insertion of a heterologous DNA Binding Domain (DBD), wherein:
(i) the DNA modifying enzyme is Cre or a Cre-derived recombinase and the DBD is inserted between amino acid positions 278 and 279; or
(ii) the DNA modifying enzyme is Vika or a Vika-derived recombinase and the DBD is inserted between amino acid positions 172 and 173; or
(iii) the DNA modifying enzyme comprises an amino acid sequence having at least 80% sequence identity to any one of SEQ ID NOs: 5, 9 to 13, 19, 20, 22, 30, 41, 42, 51, 64 and 91 to 200.
